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Abstract
Hepatitis B (HBV) reactivation induced by chemotherapy 
is problem encountered recently in the management of 
malignant diseases. Chemotherapy-induced HBV reacti-
vation may ultimately lead to terminal acute liver failure. 
Liver transplantation (LT) currently remains the only de-
finitive treatment option for such cases, but is generally 
denied to patients suffering from malignancy. Here, the 
authors describe 2 cases of cancer-free and HBV graft 
re-infection-free survival after LT performed for terminal 
liver failure arising from HBV reactivation induced by 
chemotherapy for advanced stage lymphoma. These 2 
cases, and some other reports in the literature, may sug-
gest that patients suffering from hematologic malignan-
cies and terminal liver disease can be considered for LT 
if the prognosis of their hematologic malignancy is good.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Reactivation of  a previous hepatitis B virus (HBV) 
infection is a known complication in patients undergo-
ing chemotherapy or immunosuppressive treatment. 
Such reactivations have been observed in HB surface 
antigen (HBsAg) positive and negative subjects, with an 
incidence of  26% to 47%[1,2]. Although lamivudine pro-
phylaxis is considered as the treatment of  choice in such 
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situations, in some cases it may not prevent reactivation 
of  the underlying infection[3]. Chemotherapy-induced 
HBV reactivation may then lead to terminal liver failure, 
with very limited treatment options, as life-saving liver 
transplantation (LT) is generally not performed in pa-
tients suffering from preexisting extrahepatic malignan-
cies[4]. We report 2 cases of  long-term cancer-free and 
HBV graft re-infection-free survival after LT for HBV 




A 49-year-old Caucasian male was diagnosed with ad-
vanced nodular sclerotic Hodgkin’s lymphoma stage 
IIIb-IV in January 2006. In the following month, che-
motherapy was initiated using 4 cycles of  escalated 
BEACOPP regimen (bleomycin, etoposide, adriamycin, 
cyclophosphamide, oncovin, procarbazine, prednisone). 
After 3 cycles, blood analyses indicated an acute HBV 
infection (HBsAg+, anti-HBc+). Indeed, prior to che-
motherapy, the patient had been an HBsAg carrier, a 
status he had failed to mention initially. Further blood 
tests confirmed the revised diagnosis of  chronic HBV 
infection (anti-HBs-, anti-HBe+). His hepatic function 
was closely monitored and the last cycle of  escalated 
BEACOPP was administered in April 2006. A follow-up 
positron emission tomography (PET) revealed signifi-
cant lymphoma regression, after which the patient was 
switched to a baseline BEACOPP pattern, to minimize 
adverse effects.
One month later, after the first cycle of  baseline 
BEACOPP chemotherapy, the patient was admitted to 
hospital with fatigue, anorexia, generalized edema and 
jaundice. Blood analysis showed significant alteration of  
liver function (aspartate aminotransferase: 505 IU/L, 
alanine aminotransferase: 300 IU/L, lactate dehydro-
genase: 579 IU/L, T-bilirubin 45.9 mg/L), and further 
chemotherapy had to be postponed. Polymerase chain 
reaction for HBV-DNA was performed with positive 
results (HBV-DNA > 10 000 000 copies). Lamivudine 
therapy was then initiated. In June 2006 the patient pre-
sented with liver failure (MELD (Model for End-stage 
Liver Disease) score 35, Quick < 20%, Factor V < 20%, 
international normalized ratio > 5) and hepatic encepha-
lopathy. Additional serology performed for other patho-
gens remained negative (human immunodeficiency virus, 
HCV, cytomegalovirus, Epstein-Barr virus, herpes sim-
plex virus, toxoplasmosis), so that hepatic failure could 
only be attributed to the reactivation of  the underlying 
HBV infection. He was then referred to our university 
hospital for LT evaluation, despite the fact that the last 
cycles of  chemotherapy had not yet been administered. 
As the last PET showed no residual lymphoma activity, 
an emergency LT was performed. Immunosuppression 
was initialized using tacrolimus, mycophenolate mofetil 
and prednisone. Graft reinfection was prevented using 
anti-Hbs immunoglobulin injections and lamivudine. No 
further chemotherapy was administered. In the first 4 
years of  follow-up, regular computed tomography (CT) 
and PET scans did not show any evidence of  lymphoma 
activity. Immunosuppressive treatment was gradually ta-
pered as in other LT recipients. At 4-year follow-up, the 
patient was alive and well, cancer-free and HBV-free, on 
long-acting tacrolimus monotherapy and HBV preven-
tion bi-therapy (lamivudine + anti-HBs immunoglobulin 
injections).
Case 2
A 53-year-old female originating from central Africa 
was diagnosed with big cell lymphoma type B of  the 
stomach, with thoracic involvement in December 2006. 
Staged as IIIa, the patient underwent poly-chemotherapy 
using a R-ACVBP regimen (rituximab, doxorubicin, cy-
clophosphamide, vindesine, bleomycin, prednisone). The 
last chemotherapy was administered in March 2007, and 
she was considered in full remission (negative PET, CT 
and gastroscopy). Despite her hepatitis B status (HBAg+, 
anti-HBc+, anti-HBs-, anti-HBe+) being known before 
chemotherapy initiation no preventive therapy was taken, 
and HBV reactivation was diagnosed in November 2007 
(positive PCR). The patient immediately received lamivu-
dine, which proved ineffective, resulting in terminal he-
patic failure (MELD-score 29, Quick < 23%, Factor V < 
30%) in March 2008. The patient was then referred for 
LT evaluation. An urgent LT has then been performed 
since stage 2 to 3 encephalopathy became apparent. Be-
cause of  severe coagulopathy, hemostatis was difficult 
during the LT procedure, and splenectomy had to be 
performed at the same time. Pathology of  the spleen did 
not reveal lymphoma. Graft HBV reinfection was pre-
vented by anti-Hbs immunoglobulin injections and lami-
vudine, and initial immunosuppression consisted of  ta-
crolimus, mycophenolate mofetil and prednisone, rapidly 
tapered. At 2-year follow-up, the patient was alive and 
well, and her immunosuppressive medication has been 
adjusted to long-acting tacrolimus monotherapy. She did 
not develop any sign of  HBV or lymphoma recurrence.
DISCUSSION
This article reports 2 patients with lymphoma who un-
derwent successful LT for chemotherapy-induced HBV 
reactivation. These cases demonstrate that life-saving 
LT should not be denied as an absolute contraindication 
in patients with lymphoma and chemotherapy-induced 
HBV reactivation. This concept confirms other reports 
suggesting that patients suffering from hematological 
diseases show low recurrence rates after LT[5,6]. These 
cases offer the opportunity to reconsider current LT 
limitations, particularly in those instances where trans-
plantation would usually be denied. The authors con-
sider that patients suffering from preexisting malignant 
diseases should not be excluded by default for this life-
saving procedure, but that potential benefits and risks 
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must be evaluated individually particularly in malignant 
lesions affecting a younger and fitter population. This 
view was also recommended by the King’s College Hos-
pital group[7].
Reactivation of  a previous HBV infection is an en-
tity regularly encountered with chemotherapy. Cases of  
fatal fulminant or subacute HBV liver failure following 
chemotherapy for lymphoma have been reported[8-10]. 
This is particularly true in cases in which rituximab and 
corticosteroids are included in the protocol[1,2,8]. The 
pathophysiology remains to be determined, but reports 
suggest that immunosuppressants favor viral reproduc-
tion, and that a massive immunological reaction occurs 
as soon as normal immune system function is reestab-
lished at the end of  chemotherapy. This overwhelming 
immune response is the origin of  hepatic acute cytoly-
sis[1]. Reports suggest that every patient undergoing 
chemotherapy should be checked for previous HBV 
infection, and that HBV preventive treatment through-
out the patient’s chemotherapy should be performed in 
case of  previous HBV infection. However, at the time 
of  treatment of  the 2 patients mentioned in this case 
report, lamivudine prophylaxis was not reimbursed by 
the Belgian health system so that it was administered 
only after reactivation had already occurred. Nonetheless 
in some cases, lamivudine prophylaxis may not prevent 
reactivation, and terminal or fulminant liver failure may 
occur[3]. Urgent LT is the only effective treatment[11,12] 
but is usually denied because of  the underlying malig-
nancy. To the best of  the authors’ knowledge, only a few 
cases of  LT in this particular setting have been reported 
so far[5,8,13]. This suggests that patients suffering from 
hematologic diseases seem to constitute a subgroup in 
which the reoccurrence rate after LT seems to be low. 
These 2 cases do support these observations. To some 
extent these observations can be explained by the new 
treatment possibilities and the recent outcome improve-
ments that have been made over the last few decades in 
the management of  hematologic diseases. New chemo-
therapy regimens, as well as new methods (e.g. PET) to 
assess the efficiency of  ongoing treatments, are being 
continuously developed, allowing tailored therapies for 
each patient, rendering this condition highly curable. 
Current studies suggest that an escalated BEACOPP 
regimen is the treatment of  choice for advanced Hodg-
kin lymphoma, and has an overall chance of  96% to 
achieve full remission with a 5 year survival rate peaking 
at 92%[14-16]. Other complications such as veno-occlusive 
disease or graft-versus-host disease following bone mar-
row transplantation may also cause terminal liver failure 
in patients treated for hematologic malignancies. Though 
experience is limited, reports indicate that LT may also 
be a feasible and effective approach in such cases[17-19]. 
Recurrence of  the underlying preexisting malignancy 
may occur after LT, promoted by the necessary immuno-
suppression and by a direct effect of  calcineurin inhibi-
tors[4,20]. However, in cancer patients with good prognosis, 
as in the 2 lymphoma patients described here, LT may 
be life-saving. In the absence of  large studies, each pa-
tient should be assessed individually to evaluate if  organ 
transplantation can be beneficial in terms of  survival and 
quality of  life. Further studies with longer follow-up are 
needed to establish prognostic factors to identify those 
patients in whom LT can be considered as an effective ap-
proach. 
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